Please assess the completion status of the following clinical trial:

Trial Title: Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are between ages 18-65 years old.~* Meet DSM-IV criteria for nicotine dependence.~* Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1 month) and have an expired breath CO level \> 10.~* At the time of initial evaluation, are motivated to quit smoking in the next 30 days.~* Receive a score of ≥ 10 on the Insomnia Severity Index (ISI)~* Have the capacity to give informed consent, and are English-speaking.~Exclusion Criteria:~* Are taking an over-the-counter or prescription medications that are known to affect sleep.~* Are taking medications contraindicated for use with eszopiclone or bupropion including: Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Nefazodone, Troleandomycin, Ritonavir, Nelfinavir, Trazodone, and Methadone.~* Are using any over-the-counter analgesics that contain caffeine.~* Have serious medical disorders that may make participation in the trial unsafe.~* Are physiologically dependent on and/or abusing alcohol or other drugs of abuse (e.g., cocaine, opiates, benzodiazepines, etc.) in the past 6 months prior to randomization into the trial.~* Consume greater than 1 alcoholic beverage per day or greater than 7 alcoholic drinks per week.~* Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder or post-traumatic stress disorder, or a current or past history bipolar disorder, schizophrenia, or anorexia or bulimia nervosa. Have a past history of major depression, with historical evidence of suicidal or homicidal behavior, or psychotic symptoms.~* Have the presence of suicidal or homicidal ideation, or significant impairment of social or occupational functioning, either at study baseline during the evaluation process, or during participation in the trial.~* Are from the same household as another study participant.~* A history of seizures of any etiology.~* A history of hypersensitivity to bupropion or Lunesta (eszopiclone).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Zyban + Lunesta (Type: EXPERIMENTAL): Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
- Zyban + Placebo (Type: PLACEBO_COMPARATOR): Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).